Zydus Therapeutics reports positive phase-3 results in rare liver disease
Saroglitazar was generally well tolerated, with overall adverse events generally balanced between Saroglitazar-treated and placebo-treated patients
Saroglitazar was generally well tolerated, with overall adverse events generally balanced between Saroglitazar-treated and placebo-treated patients
LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis
Guidelines aim to establish state-regulated veterinary blood banks
KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB
Astaxanthin is a powerful antioxidant and red-orange carotenoid pigment found in various aquatic organisms
Rocket will also collaborate with investigators to implement an immunomodulatory regimen more closely reflecting that administered in the Phase 1 pediatric cohort
This system enables comprehensive diagnosis of both acid and non-acid reflux, along with esophageal motility disorders.
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
AINU is set to accelerate its expansion footprint, enhance operational capabilities
Subscribe To Our Newsletter & Stay Updated